Epoch 12: Translating Innovation into Breakthrough Products

Biology, Clinical, Regulatory

Welcome to the 18 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,101 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. Over the past few weeks (not including our detour for the SVB weekend) we have been running through a deep dive on innovation trends across the biopharma industry.  Those discussions have been focused on trends leading up to today.  Now we shift gears and look forward - how do we see innovation in biology, clinical science, and regulatory policy shaping the industry in the years to come.  The discussion will get somewhat detailed, but there will be a little something for everyone despite which phase of the R&D pipeline you focus on.

We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.  

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!